NCT03795701View on ClinicalTrials.gov

To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity

NACompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

January 8, 2019

Primary Completion Date

May 1, 2022

Study Completion Date

May 1, 2022

Conditions
Obesity
Interventions
DRUG

Saxenda®

Receiving escalating dose of Saxenda® for the first 4 weeks (0.6mg, 1.2mg, 1.8mg, 2.4 mg) and receiving full-dose (3.0 mg) for 12 weeks.

OTHER

Placebo

Receiving equivalent volumes of the pre-filled solutions from pen-injector as Liraglutide 3.0 group .

Trial Locations (2)

79409

Texas Tech Neuroimaging Institute, Lubbock

79410

Nutrition & Metabolic Health Initiative, Lubbock

Sponsors

Collaborators (1)

Novo Nordisk A/S
All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

Texas Tech University

OTHER

NCT03795701 - To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity | Biotech Hunter | Biotech Hunter